Base to Base Biotech
Base to Base Biotech
Podcast Description
The Base to Base Biotech podcast is a weekly look at what's happening in the world of biotech, with interviews with biotech leaders around the world.Whether it's a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed.The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall.Base to Base is an Ayr Coastal Media Ltd production.
Podcast Insights
Content Themes
The podcast covers a range of topics within the biotech realm, including new drug developments, technological advancements, clinical trial results, and product launches. Specific episodes highlight innovations like non-addictive pain alternatives and wearable devices for bone health, alongside discussions on artificial intelligence in disease diagnostics and cancer immunotherapy strategies. Each episode aims to keep listeners informed and engaged with the dynamic biotech sector.
The Base to Base Biotech podcast is a weekly look at what’s happening in the world of biotech, with interviews with biotech leaders around the world.
Whether it’s a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed.
The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall.
Base to Base is an Ayr Coastal Media Ltd production.
This week, we have three interviews done during Life Sciences Baltics, which was held in Vilnius, Lithuania recently.
While we have more still to come, this week on the podcast we have conversations with Justinas Mačiulaitis, Keli Therapeutics’ founder and CEO; Arnas Karužas, CEO of Ligence; and Emilė Radytė, CEO and co-founder of Samphire Neuroscience.
Ligence
Ligence is a health‑tech startup using artificial intelligence to automate echocardiography.
Founded in 2019 by a team of medical doctors and engineers, the company’s flagship product, Ligence Heart, applies deep learning to 2D ultrasound images, automatically recognising views and performing cardiac measurements. This reduces the manual workload for clinicians and improves diagnostic consistency in heart disease monitoring.
Headquartered in Vilnius, Ligence has raised seed funding from European investors including Simpact VC and the EIC Fund, and is working to expand its AI‑driven cardiac diagnostics platform into hospitals and clinics across Europe.
Samphire Neuroscience
Samphire Neuroscience is a femtech and digital health company developing non‑invasive neurotechnology to support women’s health.
Founded in 2021, the company’s first product is a wearable headband, Nettle, that uses gentle electrical neuromodulation to alleviate symptoms associated with the menstrual cycle, such as pain, fatigue, and mood changes.
With offices in Vilnius and London, Samphire has attracted international venture backing and accelerator support, positioning itself at the intersection of neuroscience, wearables, and women’s health innovation. Its mission is to provide accessible, science‑based tools that improve quality of life for women worldwide.
Keli Therapeutics
Keli Therapeutics is advancing next‑generation cell therapies for acute and chronic inflammatory conditions.
Its lead candidate, KELI‑101, is designed to prevent acute kidney injury (AKI) following cardiac bypass surgery — a complication that often progresses to chronic kidney disease. In September 2025, Keli announced a strategic manufacturing partnership with Bramble Bio to scale production of KELI‑101, pairing its activated perinatal‑origin mesenchymal stromal cells with Bramble’s cGMP expertise.
Earlier this year, the company also secured a €2.5m European Innovation Council grant to launch clinical trials in AKI. With a platform up to 20 times more potent than standard MSCs, Keli is positioning itself as a leader in regenerative medicine with broad potential across inflammatory and degenerative diseases.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email [email protected]
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.